Biophytis Biopharmaceutical (Hong Kong) Group Limited
Accelerate Access to BIO101 for sarcopenia patients in Asia
Our Mission
Biophytis Biopharmaceutical (Hong Kong) Group Limited is a strategic joint venture created to develop and commercializeBIO101is Biophytis' innovative candidate for the treatment ofSarcopenia。
A Major Strategic Partnership
This joint venture stems from Biophytis a strategic alliance between a consortium of leading Asian partnersbringing together diversified resources and expertise to jointly accelerate the development and commercialization of BIO101 in Asian markets.
- Commitment focused on the development and commercialization of BIO101 in Asia
- A balanced capital structure
- Collaborative governance
Program Highlights:SARA-31 Asian Study
At the heart of this partnership is the launch of an internationalPhase III clinical study, named SARA-31。
Objectives of the SARA-31 study
- Obtain conditionalMarketing Authorization (MA) for BIO101 in sarcopenia
- inAsia and EuropeSubmit a Marketing Authorization Application
- Validate the efficacy and safety of BIO101 in international sarcopenia patient populations
This study is a key step in expanding access to this innovative therapy for elderly people with progressive muscle loss.
AboutSarcopenia
Sarcopenia is age-related progressive loss of muscle mass and function, representing amajor public health challenge. In Asia, population aging is accelerating. BIO101 aims to provide a first-in-class innovative therapy for this disease, for which no approved treatment currently exists.
Contact Us
Biophytis Biopharmaceutical (Hong Kong) Group Limited
Room 1111, 11/F, Hollywood Plaza
610 Nathan Road, Mong Kok
Hong Kong
